Literature DB >> 28057447

Antidepressant Prescribing by Pediatricians: A Mixed-Methods Analysis.

Anne K Tulisiak1, Jillian A Klein2, Emily Harris3, Marissa J Luft1, Heidi K Schroeder1, Sarah A Mossman1, Sara T Varney1, Brooks R Keeshin4, Sian Cotton5, Jeffrey R Strawn6.   

Abstract

Among pediatricians, perceived knowledge of efficacy, tolerability, dosing, and side effects of antidepressants represent significant sources of variability in the use of these medications in youth with depressive and anxiety disorders. Importantly, the qualitative factors that relate to varying levels of comfort with antidepressants and willingness to prescribe are poorly understood. Using a mixed-methods approach, in-depth interviews were conducted with community-based and academic medical center-based pediatricians (N = 14). Interviews were audio recorded and iteratively coded; themes were then generated using inductive thematic analysis. The relationship between demographic factors, knowledge of antidepressants, dosing, and side effects, as well as prescribing likelihood scores for depressive disorders, anxiety disorders or co-morbid anxiety and depressive disorders, were evaluated using mixed models. Pediatricians reported antidepressants to be effective and well-tolerated. However, the likelihood of individual physicians initiating an antidepressant was significantly lower for anxiety disorders relative to depressive disorders with similar functional impairment. Pediatricians considered symptom severity/functional impairment, age and the availability of psychotherapy as they considered prescribing antidepressants to individual patients. Antidepressant choice was related to the physician׳s perceived knowledge and comfort with a particular antidepressant, financial factors, and the disorder-specific evidence base for that particular medication and consultation with mental health practitioners. Pediatricians noted similar efficacy and tolerability profiles for antidepressants in youth with depressive disorders and anxiety disorders, but tended to utilize "therapy first" approaches for anxiety disorders relative to depressive disorders. Parental and family factors that influenced prescribing of antidepressants by pediatricians included parental ambivalence, family-related dysfunction and impairment secondary to the child׳s psychopathology as well as the child׳s psychosocial milieu. Pediatricians consider patient- and family-specific challenges when choosing prescribing antidepressant medications and are, in general, less likely to prescribe antidepressants for youth with anxiety disorders compared to youth with depressive disorders. The lower likelihood of prescribing antidepressants for anxious youth is not related to perception of the efficacy or tolerability, but rather to a perception that anxiety disorders are less impairing and more appropriately managed with psychotherapy.
Copyright © 2016 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28057447      PMCID: PMC5340594          DOI: 10.1016/j.cppeds.2016.11.009

Source DB:  PubMed          Journal:  Curr Probl Pediatr Adolesc Health Care        ISSN: 1538-3199


  34 in total

1.  Parental anxiety as a predictor of medication and CBT response for anxious youth.

Authors:  Araceli Gonzalez; Tara S Peris; Allison Vreeland; Cara J Kiff; Philip C Kendall; Scott N Compton; Anne Marie Albano; Boris Birmaher; Golda S Ginsburg; Courtney P Keeton; John March; James McCracken; Moira Rynn; Joel Sherrill; John T Walkup; John Piacentini
Journal:  Child Psychiatry Hum Dev       Date:  2015-02

2.  An exploratory analysis of the impact of family functioning on treatment for depression in adolescents.

Authors:  Norah C Feeny; Susan G Silva; Mark A Reinecke; Steven McNulty; Robert L Findling; Paul Rohde; John F Curry; Golda S Ginsburg; Christopher J Kratochvil; Sanjeev M Pathak; Diane E May; Betsy D Kennard; Anne D Simons; Karen C Wells; Michele Robins; David Rosenberg; John S March
Journal:  J Clin Child Adolesc Psychol       Date:  2009-11

3.  A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder.

Authors:  Jeffrey R Strawn; Apurva Prakash; Qi Zhang; Beth A Pangallo; Chad E Stroud; Na Cai; Robert L Findling
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2015-01-29       Impact factor: 8.829

4.  The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders.

Authors:  D S Pine; P Cohen; D Gurley; J Brook; Y Ma
Journal:  Arch Gen Psychiatry       Date:  1998-01

5.  Associations of fearful spells and panic attacks with incident anxiety, depressive, and substance use disorders: a 10-year prospective-longitudinal community study of adolescents and young adults.

Authors:  Eva Asselmann; Hans-Ulrich Wittchen; Roselind Lieb; Michael Höfler; Katja Beesdo-Baum
Journal:  J Psychiatr Res       Date:  2014-04-12       Impact factor: 4.791

6.  Pediatricians' role in providing mental health care for children and adolescents: do pediatricians and child and adolescent psychiatrists agree?

Authors:  Amy Heneghan; Andrew S Garner; Amy Storfer-Isser; Karl Kortepeter; Ruth E K Stein; Sarah McCue Horwitz
Journal:  J Dev Behav Pediatr       Date:  2008-08       Impact factor: 2.225

7.  Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.

Authors:  David Brent; Graham Emslie; Greg Clarke; Karen Dineen Wagner; Joan Rosenbaum Asarnow; Marty Keller; Benedetto Vitiello; Louise Ritz; Satish Iyengar; Kaleab Abebe; Boris Birmaher; Neal Ryan; Betsy Kennard; Carroll Hughes; Lynn DeBar; James McCracken; Michael Strober; Robert Suddath; Anthony Spirito; Henrietta Leonard; Nadine Melhem; Giovanna Porta; Matthew Onorato; Jamie Zelazny
Journal:  JAMA       Date:  2008-02-27       Impact factor: 56.272

8.  Incidence and risk patterns of anxiety and depressive disorders and categorization of generalized anxiety disorder.

Authors:  Katja Beesdo; Daniel S Pine; Roselind Lieb; Hans-Ulrich Wittchen
Journal:  Arch Gen Psychiatry       Date:  2010-01

9.  Effects of Food and Drug Administration warnings on antidepressant use in a national sample.

Authors:  Mark Olfson; Steven C Marcus; Benjamin G Druss
Journal:  Arch Gen Psychiatry       Date:  2008-01

10.  What characteristics of primary anxiety disorders predict subsequent major depressive disorder?

Authors:  Antje Bittner; Renee D Goodwin; Hans-Ulrich Wittchen; Katja Beesdo; Michael Höfler; Roselind Lieb
Journal:  J Clin Psychiatry       Date:  2004-05       Impact factor: 4.384

View more
  7 in total

1.  CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study.

Authors:  Jeffrey R Strawn; Ethan A Poweleit; Laura B Ramsey
Journal:  J Child Adolesc Psychopharmacol       Date:  2019-02-28       Impact factor: 2.576

Review 2.  Pharmacogenomic Testing in Child and Adolescent Psychiatry: An Evidence-Based Review.

Authors:  Anna M Wehry; Laura Ramsey; Shane E Dulemba; Sarah A Mossman; Jeffrey R Strawn
Journal:  Curr Probl Pediatr Adolesc Health Care       Date:  2018-01-08

Review 3.  Antidepressant-Induced Activation in Children and Adolescents: Risk, Recognition and Management.

Authors:  Marissa J Luft; Martine Lamy; Melissa P DelBello; Robert K McNamara; Jeffrey R Strawn
Journal:  Curr Probl Pediatr Adolesc Health Care       Date:  2018-01-19

4.  A Double-Blind Randomized Trial to Investigate Mechanisms of Antidepressant-Related Dysfunctional Arousal in Depressed or Anxious Youth at Familial Risk for Bipolar Disorder.

Authors:  Duncan C Honeycutt; Melissa P DelBello; Jeffrey R Strawn; Laura B Ramsey; Luis R Patino; Kyle Hinman; Jeffrey Welge; David J Miklowitz; Booil Jo; Thomas J Blom; Kaitlyn M Bruns; Sarah K Hamill Skoch; Nicole Starace; Maxwell J Tallman; Manpreet K Singh
Journal:  J Pers Med       Date:  2022-06-20

5.  Acute neurofunctional effects of escitalopram during emotional processing in pediatric anxiety: a double-blind, placebo-controlled trial.

Authors:  Lu Lu; Hailong Li; William T Baumel; Jeffrey A Mills; Kim M Cecil; Heidi K Schroeder; Sarah A Mossman; Xiaoqi Huang; Qiyong Gong; John A Sweeney; Jeffrey R Strawn
Journal:  Neuropsychopharmacology       Date:  2021-09-27       Impact factor: 8.294

6.  Pharmacogenetically Guided Escitalopram Treatment for Pediatric Anxiety Disorders: Protocol for a Double-Blind Randomized Trial.

Authors:  Jeffrey R Strawn; Ethan A Poweleit; Jeffrey A Mills; Heidi K Schroeder; Zoe A Neptune; Ashley M Specht; Jenni E Farrow; Xue Zhang; Lisa J Martin; Laura B Ramsey
Journal:  J Pers Med       Date:  2021-11-12

7.  Medication Management of Anxiety and Depression by Primary Care Pediatrics Providers: A Retrospective Electronic Health Record Study.

Authors:  Talia R Lester; Yair Bannett; Rebecca M Gardner; Heidi M Feldman; Lynne C Huffman
Journal:  Front Pediatr       Date:  2022-03-17       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.